<DOC>
	<DOCNO>NCT00830505</DOCNO>
	<brief_summary>The purpose study compare effect Fluticasone/ salmeterol combination double dose fluticasone airway hyper-responsiveness methacholine .</brief_summary>
	<brief_title>Fluticasone/Salmeterol ( FP/SM ) Versus Double Dose Fluticasone ( FP ) Patients With Mild Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>1 . Written informed consent give patient . 2 . Male female patient 18 65 year age inclusive . 3 . Persistent stable asthmatic ( FEV1 &gt; 60 % ) 4 . On ≤ 1000 µg FP equivalent combination therapy 500 µg FP equivalent ( e.g . FP/SM 125 2puffs BD BUD/FM 200/6 2puffs BD ) 5 . Patients suffer stable , persistent , mild moderate asthma define GINA Guidelines FEV1 &gt; 60 % 6 . In opinion investigator , able willing comply requirement protocol . 1 . Severe asthmatic define FEV1 &lt; 60 % PEF variability &gt; 30 % continual daytime nocturnal symptom . 2 . Known suspected hypersensitivity FP constituents Test Reference pMDI 3 . Any clinically significant medical condition abnormality , , opinion investigator , might compromise safety patient might interfere study ( unstable angina , acute myocardial infarction precede 3 month , recent TIA / CVA ) . 4 . Females pregnant , lactate plan become pregnant . 5 . Approximately half subject smoker half currently nonsmoker ( cease smoking least 1 year previously ) . 6 . Clinically significant laboratory value , judge investigator . 7 . Receipt investigational drug within 30 day 5 halflives , whichever longer , prior screen visit . 8 . Patients schedule receive investigational drug course study . 9 . Concomitant use medicine ( prescribe , counter herbal ) may interfere trial . 10 . Exacerbations asthma require oral steroid , hospitalisation change asthma therapy previous three month . 11 . Respiratory tract infection previous 2 month . 12 . Patients significant concomitant respiratory disease COPD , CF , ABPA , active pulmonary TB bronchiectesis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>fluticasone</keyword>
	<keyword>salmeterol</keyword>
	<keyword>bronchoprotection</keyword>
</DOC>